Back to Journals » Cancer Management and Research » Volume 11

Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors

Authors Ni Z, Zhang L, Zheng J, Su X, Zhang S

Received 24 May 2019

Accepted for publication 3 August 2019

Published 6 November 2019 Volume 2019:11 Pages 9421—9425

DOI https://doi.org/10.2147/CMAR.S216971

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly


Zexu Ni,1,* Lingling Zhang,2,3,* Jinhua Zheng,1 Xiaojie Su,1 Shucai Zhang2

1Department of Pathology, Dongguan Tungwah Hospital, Dongguan 523110, People’s Republic of China; 2Department of Oncology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, People’s Republic of China; 3Department of Oncology, Peking University International Hospital, Beijing 102206, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Shucai Zhang
Department of Oncology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, People’s Republic of China
Email sczhang6304@163.com

Objective: Brain metastasis (BM) is a serious complication of advanced lung adenocarcinoma and is a prominent factor leading to lung cancer mortality. In this study, the expression of the glycodelin protein was analyzed in EGFR-mutant tyrosine kinase inhibitor-sensitive advanced lung adenocarcinoma.
Methods: This study features a retrospective analysis of 74 advanced lung adenocarcinoma patients treated at our hospital from January 2010 to December 2017. The expressions of glycodelin were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes.
Results: Patients with advanced lung adenocarcinoma with glycodelin overexpression were prone to BM (P < 0.05), and exhibited significantly shortened OS (11.8 months vs 20.4 months, P < 0.05). Multivariate regression analysis showed that overexpression of glycodelin and brain metastases were independent factors affecting the prognosis of advanced lung adenocarcinoma (P < 0.05).
Conclusion: The overexpression of glycodelin is closely related to the presence of brain metastasis in lung adenocarcinoma, and can be used as an auxiliary diagnostic index for prognosis of advanced lung adenocarcinoma.

Keywords: glycodelin, advanced lung adenocarcinoma, brain metastasis, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]